Category Archives: BigPharma

TX AG Investigating 2 Pharmaceuticals For DeceptiveTrade Practices

.jpg photo of Texas Attorney General LogoAG Paxton to Investigate Promotion of Puberty Blockers in Children

AUSTIN, TX  –  Texas Attorney General Ken Paxton is investigating Endo Pharmaceuticals, Inc., and AbbVie Inc. under the Texas Deceptive Trade Practices Act.  These pharmaceutical companies allegedly advertised and promoted hormone (puberty) blockers for unapproved uses without disclosing the potential risks associated with these drugs to children and their parents.

Medications Supprelin LA and Lupron Depot are approved to treat children with Central Precocious Puberty (CPP), when the puberty process begins prematurely.   And Vantas, along with other forms of Lupron, has been prescribed for palliative treatment of prostate cancer.  These drugs are now being used to treat gender dysphoria even though they are not approved for such use by the Food and Drug Administration (FDA).  Gender dysphoria is a diagnosed mental disorder in which a person experiences significant distress related to a strong desire to be of another biological sex.

“The manufacture, sale, prescription, and use of puberty blockers on young teens and minors is dangerous and reckless,” Attorney General Ken Paxton said.  “These drugs were approved for very different purposes and can have detrimental and even irreversible side effects.  I will not allow pharmaceutical companies to take advantage of Texas children.”

The OAG has the authority to investigate false, misleading, and deceptive conduct by businesses in Texas, and to take legal action to enforce the Texas Deceptive Trade Practices Act.

Read letter HERE

TX Attorney General Still Fighting‎ Medicaid Fraud

.jpg photo of Texas Attorney General Logo
Big Pharma pays price for reporting inflated drug prices.

Paxton Recovers $26 Million for the State of Texas, Medicaid Program

AUSTIN, TX  –  Attorney General Ken Paxton resolved an enforcement action against pharmaceutical manufacturer Apotex for reporting inflated drug prices to the Texas Medicaid program.  Under the agreement, Apotex will pay Texas $26 million to resolve claims against it.

This settlement is the latest recovery in price reporting cases the Attorney General has brought under the Texas Medicaid Fraud Prevention Act since 1999, resulting in a cumulative recovery for Texas taxpayers of over $2.3 billion.

“Thanks to our Civil Medicaid Fraud Division’s commitment to Texas taxpayers, identifying and preventing Medicaid fraud continues to be a top priority in my office,” Attorney General Paxton said.  “We will not allow pharmaceutical companies to take advantage of vulnerable Texans, and we will continue to be vigilant in cracking down on any abuse of this important program.”

Read the agreement here.